Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Abbott GmbH & Co. KG
Femme et Homme Max 99 ans
Abbott GmbH & Co. KG
MAJ Il y a 4 ans
A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL) Sperimentazione di ABT-263 in associazione con Rituximab dose-intensive o di Rituximab dose-intensive da solo in pazienti con leucemia linfocitica cronica (CLL) a cellule B non precedentemente trattati
To evaluate the efficacy of ABT-263 when given according to two different regimens in combination with doseintense rituximab in previously untreated patients with B-cell CLL, as measured by progressio...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Abbott GmbH & Co. KG
MAJ Il y a 4 ans
A Multicenter, Double-Blind Study to Evaluate the Safety, Efficacy and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Pediatric Subjects with Moderate to Severe Crohn's Disease
To demonstrate the safety and efficacy of adalimumab and to assess the pharmacokinetics (PK) of adalimumab administered by SC injection in pediatric subjects with moderate to severe CD.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Abbott GmbH & Co. KG
MAJ Il y a 4 ans
A Multi-center, Randomized, Double-blind, Placebo − controlled Study Comparing 80 mg of Adalimumab with Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing
To demonstrate the efficacy of 80 mg adalimumab monthly dosing compared with placebo as measured by ACR20 response criteria following 12 weeks of therapy. The study is also designed to demonstrate the...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Abbott GmbH & Co. KG
MAJ Il y a 4 ans
The PRIMO II Study: Paricalcitol Injection benefits in Renal failure Induced cardiac Morbidity in Subjects with Chronic Kidney Disease Stage 5
To investigate the effects of paricalcitol injection on progression or regression of LVH in subjects with Stage 5 CKD receiving hemodialysis compared to placebo, as assessed by comparing changes in LV...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Abbott GmbH & Co. KG
MAJ Il y a 4 ans
A Phase 2 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Chronic Hidradenitis Suppurativa
The primary objective of this study is to determine the clinical efficacy and safety of adalimumab in subjects with moderate to severe chronic hidradenitis suppurativa (HS) after 16 weeks of treatment...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Abbott GmbH & Co. KG
MAJ Il y a 4 ans
A study in Rheumatoid Arthritis patients to look at two formulations of adalimumab for pharmacokinetics and safety
To compare the new adalimumab formulation to the currently approved (current) adalimumab formulation in a dosing regimen of 40 mg eow for 24 weeks
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Abbott GmbH & Co. KG
MAJ Il y a 4 ans
A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study of Carboplatin /Paclitaxel in Combination with ABT-869 Versus Carboplatin/Paclitaxel Alone in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) as First-Line Treatment
To assess if the addition of oral ABT-869 to carboplatin and paclitaxel can prolong progression-free survival (PFS) compared to carboplatin and paclitaxel alone in subjects with NSCLC.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Abbott GmbH & Co. KG
MAJ Il y a 4 ans
A Multi-Centre, Open-Label, Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects who Completed a Preceeding Psoriasis Clinical Study with Adalimumab
To evaluate the long term safety, tolerability and clinical efficacy of adalimumab in subjects with moderate to severe chronic plaque psoriasis entering from studies M02-529,M02-538, M03-596 and the p...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Abbott GmbH & Co. KG (Abbott)
MAJ Il y a 4 ans
A study of the efficacy and safety of adalimumab in pediatric subjects with enthesitis related arthritis
The objectives of this study are to evaluate the efficacy and safety of adalimumab given subcutaneously every other week (eow) as compared to placebo in pediatric subjects with Enthesitis Related Arth...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Précédent
1
2
3
4
5